Skip to main content
Livermore
Livermore
ZHEN

D. E. Shaw & Co., Inc.

SEC CIK
0001009207
Latest filing
Aug 14, 2026

BCRX holding history

Biocryst Pharmaceuticals Inc in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

BCRX overviewAll 13F holders of BCRXFull Q2 2026 holdings

Shares (Q2 2026)
408,529
Value
$4.09M
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of BCRX by D. E. Shaw & Co., Inc., by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026408,529$4.09M<0.1%+106,428+35.2%AddedHolders
Q1 2026302,101$2.88M<0.1%−945,365−75.8%ReducedHolders
Q4 20251,247,466$9.73M<0.1%−461,870−27.0%ReducedHolders
Q3 20251,709,336$13.0M<0.1%−2,680,141−61.1%ReducedHolders
Q2 20254,389,477$39.3M<0.1%+2,800,365+176.2%AddedHolders
Q1 20251,589,112$11.9M<0.1%+1,273,849+404.1%AddedHolders
Q4 2024315,263$2.37M<0.1%+86,173+37.6%AddedHolders
Q3 2024229,090$1.74M<0.1%−121,710−34.7%ReducedHolders
Q2 2024350,800$2.17M<0.1%+316,924+935.5%AddedHolders
Q1 202433,876$172.1K<0.1%+3,245+10.6%AddedHolders
Q4 202330,631$183.5K<0.1%+30,631NewHolders
Q3 20230$00.0%−10,403−100.0%Sold outHolders
Q2 202310,403$73.2K<0.1%−123,320−92.2%ReducedHolders
Q1 2023133,723$1.12M<0.1%−399,530−74.9%ReducedHolders
Q4 2022533,253$6.12M<0.1%+37,714+7.6%AddedHolders
Q3 2022495,539$6.24M<0.1%+495,539NewHolders
Q2 20220$00.0%−519,050−100.0%Sold outHolders
Q1 2022519,050$8.44M<0.1%−613,215−54.2%ReducedHolders
Q4 20211,132,265$15.7M<0.1%+159,731+16.4%AddedHolders
Q3 2021972,534$14.0M<0.1%+100,008+11.5%AddedHolders
Q2 2021872,526$13.8M<0.1%+811,723+1,335.0%AddedHolders
Q1 202160,803$618.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.